CDKN2A and acute lymphoblastic leukemia: In addition, the use of cyclin-dependent kinase inhibitors (CDKIs) in CDKN2A/2B-affected ALL pediatric subgroups requires prospective evaluation in the framework of targeted therapies and controlled clinical trials.